SCHEMBL1147609

SCHEMBL1147609

NC1CCCC(Nc2ccnc3cc(Cl)ccc23)C1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT5B Q4FZB7 2/20 0.74
KMT5C Q86Y97 2/20 0.74
NSD2 O96028 1/20 0.59
CYP2D6 P10635 2/20 0.58
CYP2C19 P33261 1/20 0.58
KMT2A Q03164 3/20 0.57
ALDH1A1 P00352 2/20 0.57
MEN1 O00255 2/20 0.57
KDM4E B2RXH2 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.55
HPGD P15428 1/20 0.55
TSHR P16473 1/20 0.55
NR4A2 P43354 1/20 0.49
CYP1A2 P05177 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
FERMT2 Q96AC1 3/20 0.48
MAPT P10636 3/20 0.47
TDP1 Q9NUW8 3/20 0.47
CCR1 P32246 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7834821 0.93 KMT5B (0.70) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7834815 0.93 KMT5B (0.70) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7834817 0.93 KMT5B (0.70) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7205774 0.91 KMT5B (0.84) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7205707 0.91 KMT5B (0.84) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7205699 0.91 KMT5B (0.84) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7206511 0.91 KMT5B (0.84) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7206080 0.86 KMT5B (0.79) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7206069 0.86 KMT5B (0.79) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL12858988 0.85 KMT5B (0.74) KMT5BKMT5CNSD2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110045100-A1 Antimalarial Quinolines and Methods of Use Thereof GEORGETOWN UNIVERSITY (US) 2011-02-24 US disclosed
US-20110045100-A1 Antimalarial Quinolines and Methods of Use Thereof GEORGETOWN UNIVERSITY (US) 2011-02-24 US disclosed
WO-2009148659-A2 ANTIMALARIAL QUINOLINES AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2009-12-10 WO disclosed
WO-2009148659-A2 ANTIMALARIAL QUINOLINES AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110045100-A1 Antimalarial Quinolines and Methods of Use Thereof NQO2, QTRT1, QTRT2 KMT5B 999/4885KMT5C 906/4885NSD2 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.